Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Eargo Stock Is Imploding Today

By Cory Renauer – Sep 23, 2021 at 11:12AM

Key Points

  • Eargo is the target of a U.S. Department of Justice investigation regarding insurance payments.
  • Before disclosing the federal investigation, Eargo told investors about a claims audit by an insurer that's also the company's largest customer.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An investigation related to insurance claims isn't going over well with investors.

What happened

Shares of Eargo (EAR -4.02%), a hearing aid manufacturer, are sinking in response to the disclosure of a federal investigation the company made to investors after markets closed on Wednesday. The medical device stock was down 68.5% as of 10:40 a.m. EDT on Thursday.

So what 

Eargo reported net revenue that rose 44% year over year to $23 million in the second quarter, but a recent SEC disclosure has investors questioning the integrity of the company's sales figures. On Sept. 21, Eargo was informed that it is the target of a criminal investigation by the U.S. Department of Justice.

People in white coats looking embarassed.

Image source: Getty Images.

The investigation is related to insurance reimbursement claims the company submitted on behalf of customers covered by federal health plans. Eargo markets tiny rechargeable hearing aids that cost nearly $3,000 per pair. 

In August, Eargo increased its revenue forecast for 2021 to a range between $93 million and $96 million. In light of the investigation, though, the company withdrew its financial guidance for the year.

Now what

Without a way to be sure sales to insurers can remain on the company's income statement, investment banks including J.P. Morgan and Wells Fargo severely lowered their ratings on the medical device start-up. 

It's hard to guess how much of an impact the DOJ investigation will have without more details. We do know the company's largest third-party payor initiated a claims audit earlier this year. Intrepid investors thinking about catching this falling knife probably want to stand back until we know more.

Wells Fargo is an advertising partner of The Ascent, a Motley Fool company. JPMorgan Chase is an advertising partner of The Ascent, a Motley Fool company. Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eargo, Inc. Stock Quote
Eargo, Inc.
$0.53 (-4.02%) $0.02
JPMorgan Chase Stock Quote
JPMorgan Chase
$136.39 (1.52%) $2.04
Wells Fargo Stock Quote
Wells Fargo
$47.49 (1.10%) $0.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.